Literature DB >> 22391205

Glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1).

Sejeong Shin, Laura Wolgamott, Sang-Oh Yoon.   

Abstract

Entities:  

Year:  2012        PMID： 22391205     DOI： 10.4161/cc.11.6.19784

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  4 in total

1.  Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.

Authors:  Melissa Sokolosky; William H Chappell; Kristin Stadelman; Stephen L Abrams; Nicole M Davis; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

2.  GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.

Authors:  Stephen L Abrams; Shaw M Akula; Akshaya K Meher; Linda S Steelman; Agnieszka Gizak; Przemysław Duda; Dariusz Rakus; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Giuseppe Montalto; Melchiorre Cervello; Peter Ruvolo; Massimo Libra; Luca Falzone; Saverio Candido; James A McCubrey
Journal:  Cells       Date:  2021-04-06       Impact factor: 6.600

Review 3.  GSK-3 as potential target for therapeutic intervention in cancer.

Authors:  James A McCubrey; Linda S Steelman; Fred E Bertrand; Nicole M Davis; Melissa Sokolosky; Steve L Abrams; Giuseppe Montalto; Antonino B D'Assoro; Massimo Libra; Ferdinando Nicoletti; Roberta Maestro; Jorg Basecke; Dariusz Rakus; Agnieszka Gizak; Zoya N Demidenko; Lucio Cocco; Alberto M Martelli; Melchiorre Cervello
Journal:  Oncotarget       Date:  2014-05-30

Review 4.  A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease.

Authors:  Arezoo Gowhari Shabgah; Fatemeh Norouzi; Mahdiyeh Hedayati-Moghadam; Davood Soleimani; Naseh Pahlavani; Jamshid Gholizadeh Navashenaq
Journal:  Nutr Metab (Lond)       Date:  2021-02-23       Impact factor: 4.169
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.